Defining disease‐modifying therapies for PD—A road map for moving forward
Identifieur interne : 000B67 ( Main/Corpus ); précédent : 000B66; suivant : 000B68Defining disease‐modifying therapies for PD—A road map for moving forward
Auteurs : C. Warren Olanow ; Karl KieburtzSource :
- Movement Disorders [ 0885-3185 ] ; 2010-09-15.
English descriptors
- KwdEn :
Abstract
A disease‐modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long‐term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23288
Links to Exploration step
ISTEX:23D4EB7CDB1AED385F58A66A9FDD0C73647758ECLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Defining disease‐modifying therapies for PD—A road map for moving forward</title><author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:23D4EB7CDB1AED385F58A66A9FDD0C73647758EC</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23288</idno><idno type="url">https://api.istex.fr/document/23D4EB7CDB1AED385F58A66A9FDD0C73647758EC/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Defining disease‐modifying therapies for PD—A road map for moving forward</title><author><name sortKey="Warren Olanow, C" sort="Warren Olanow, C" uniqKey="Warren Olanow C" first="C." last="Warren Olanow">C. Warren Olanow</name><affiliation><mods:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-09-15">2010-09-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1774">1774</biblScope><biblScope unit="page" to="1779">1779</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">23D4EB7CDB1AED385F58A66A9FDD0C73647758EC</idno><idno type="DOI">10.1002/mds.23288</idno><idno type="ArticleID">MDS23288</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical trials</term><term>Delayed start study</term><term>Disease modification</term><term>Long term simple study</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A disease‐modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long‐term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>C. Warren Olanow MD</name><affiliations><json:string>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</json:string><json:string>Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</json:string></affiliations></json:item><json:item><name>Karl Kieburtz MD</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Disease modification</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Clinical trials</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Delayed start study</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Long term simple study</value></json:item></subject><articleId><json:string>MDS23288</json:string></articleId><language><json:string>eng</json:string></language><abstract>A disease‐modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long‐term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>5.87</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>997</abstractCharCount><pdfWordCount>4034</pdfWordCount><pdfCharCount>25032</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>153</abstractWordCount></qualityIndicators><title>Defining disease‐modifying therapies for PD—A road map for moving forward</title><genre><json:string>review-article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>6</total><last>1779</last><first>1774</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Review</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23288</json:string></doi><id>23D4EB7CDB1AED385F58A66A9FDD0C73647758EC</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/23D4EB7CDB1AED385F58A66A9FDD0C73647758EC/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/23D4EB7CDB1AED385F58A66A9FDD0C73647758EC/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/23D4EB7CDB1AED385F58A66A9FDD0C73647758EC/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Defining disease‐modifying therapies for PD—A road map for moving forward</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Defining disease‐modifying therapies for PD—A road map for moving forward</title><author><persName><forename type="first">C.</forename><surname>Warren Olanow</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, Mount Sinai School of Medicine, Annenberg 14‐94, One Gustave L. Levy Place, New York, NY 10029</p></note><affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</affiliation><affiliation>Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</affiliation></author><author><persName><forename type="first">Karl</forename><surname>Kieburtz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-09-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1774">1774</biblScope><biblScope unit="page" to="1779">1779</biblScope></imprint></monogr><idno type="istex">23D4EB7CDB1AED385F58A66A9FDD0C73647758EC</idno><idno type="DOI">10.1002/mds.23288</idno><idno type="ArticleID">MDS23288</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>A disease‐modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long‐term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>Disease modification</term></item><item><term>Clinical trials</term></item><item><term>Delayed start study</term></item><item><term>Long term simple study</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-02-10">Received</change><change when="2010-05-09">Registration</change><change when="2010-09-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/23D4EB7CDB1AED385F58A66A9FDD0C73647758EC/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v25:12</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2010-09-15">15 September 2010</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23288</doi><idGroup><id type="unit" value="MDS23288"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-02-10"></event><event type="manuscriptRevised" date="2010-03-22"></event><event type="manuscriptAccepted" date="2010-05-09"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="publishedOnlineFinalForm" date="2010-09-08"></event><event type="firstOnline" date="2010-09-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1774</numbering><numbering type="pageLast">1779</numbering></numberingGroup><correspondenceTo>Department of Neurology, Mount Sinai School of Medicine, Annenberg 14‐94, One Gustave L. Levy Place, New York, NY 10029</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23288.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="29"></count><count type="wordTotal" number="4526"></count></countGroup><titleGroup><title type="main" xml:lang="en">Defining disease‐modifying therapies for PD—A road map for moving forward<link href="#fn1"></link></title><title type="short" xml:lang="en">Disease‐Modifying Therapies for PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>C.</givenNames><familyName>Warren Olanow</familyName><degrees>MD</degrees></personName><contactDetails><email>warren.olanow@mssm.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Karl</givenNames><familyName>Kieburtz</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">Disease modification</keyword><keyword xml:id="kwd3">Clinical trials</keyword><keyword xml:id="kwd4">Delayed start study</keyword><keyword xml:id="kwd5">Long term simple study</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>A disease‐modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long‐term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Defining disease‐modifying therapies for PD—A road map for moving forward</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Disease‐Modifying Therapies for PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Defining disease‐modifying therapies for PD—A road map for moving forward</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Warren Olanow</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA</affiliation><affiliation>Department of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</affiliation><description>Correspondence: Department of Neurology, Mount Sinai School of Medicine, Annenberg 14‐94, One Gustave L. Levy Place, New York, NY 10029</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl</namePart><namePart type="family">Kieburtz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-09-15</dateIssued><dateCaptured encoding="w3cdtf">2010-02-10</dateCaptured><dateValid encoding="w3cdtf">2010-05-09</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">1</extent><extent unit="references">29</extent><extent unit="words">4526</extent></physicalDescription><abstract lang="en">A disease‐modifying therapy that slows or stops disease progression is one of the major unmet needs in the management of Parkinson's disease. To date, no therapy has been approved for disease modification despite promising laboratory data and positive results in clinical trials. This is because confounding symptomatic or pharmacologic effects cannot be excluded. The delayed start study provides an opportunity to define therapies that provide benefit that cannot be explained by an early symptomatic effect alone. However, this trial design does not necessarily provide a meaningful measure of the effect of the intervention on cumulative disability. In contrast, the long‐term simple study provides a measure of the effect of the drug on cumulative disability but does not address mechanism of action. Together these two trials provide a road map for defining a disease modifying drug and determining the long term cumulative effect of the drug on the disease. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>Disease modification</topic><topic>Clinical trials</topic><topic>Delayed start study</topic><topic>Long term simple study</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1774</start><end>1779</end><total>6</total></extent></part></relatedItem><identifier type="istex">23D4EB7CDB1AED385F58A66A9FDD0C73647758EC</identifier><identifier type="DOI">10.1002/mds.23288</identifier><identifier type="ArticleID">MDS23288</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:23D4EB7CDB1AED385F58A66A9FDD0C73647758EC
|texte= Defining disease‐modifying therapies for PD—A road map for moving forward
}}
| This area was generated with Dilib version V0.6.23. |  |